Lead-drug issues continue to pound this drug stock, but there may be light at the end of the tunnel.
Logging record highs is par for the course over the Dow's 121-year history.
Despite a strong earnings beat, not everything went J&J's way in the third quarter.
If you're on the hunt for outstanding healthcare dividend stocks, Allergan, Bristol-Myers Squibb, and McKesson need to be on your radar.
A little shine is all these gold miners need to be great once again.
Bitcoin-inspired equities are probably bad news for investors.
Don't start cheering just yet.
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
This report will be about a lot more than just a headline sales and profit figure.
Legal weed in Canada should be highly competitive with black-market pricing.
It'll probably depend on your financial and martial situation.
Surprise! Nearly twice as many Americans prefer cash to digital forms of payment.
Chances are better than not that a double-digit premium hike is headed your way.
Two of these states haven't even legalized medical cannabis.
Here's how the average American would fix Social Security.
The GDP growth rate needed to reduce national debt hasn't been achieved in 17 years.
This is the biggest raise Social Security recipients have seen in six years.
Six of 21 holdings bear particular importance to the Horizons Marijuana Life Sciences ETF.
Do you know what's in your credit report?